Furthermore, evidence from research and clinical use of the drug class has led to the initiation of clinical trials with GLP‐1 RAs in other prominent aging‐related diseases, including chronic kidney disease (CKD) and Alzheimer's disease. This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.